Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 30,300 shares, a decrease of 32.7% from the November 30th total of 45,000 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 53,000 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HOOK. JMP Securities dropped their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st. Royal Bank of Canada lowered Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $48.00 to $2.00 in a research report on Friday, December 20th.

Hookipa Pharma Stock Up 5.7 %

HOOK stock traded up $0.11 during trading on Monday, reaching $2.05. 47,608 shares of the company’s stock were exchanged, compared to its average volume of 59,057. Hookipa Pharma has a 1-year low of $1.75 and a 1-year high of $10.50. The firm has a market cap of $24.71 million, a PE ratio of -0.55 and a beta of 0.71. The company’s fifty day moving average price is $2.86 and its 200-day moving average price is $4.43.

Hedge Funds Weigh In On Hookipa Pharma

Several large investors have recently bought and sold shares of HOOK. Renaissance Technologies LLC raised its stake in shares of Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after buying an additional 83,800 shares in the last quarter. Ikarian Capital LLC bought a new stake in Hookipa Pharma in the third quarter worth about $228,000. Finally, Acadian Asset Management LLC lifted its holdings in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after acquiring an additional 108,844 shares during the last quarter. Institutional investors and hedge funds own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.